Published in Immunology on November 01, 1996
A simplification of the protein assay method of Lowry et al. which is more generally applicable. Anal Biochem (1977) 36.95
The allogeneic effect in inbred mice. II. Establishment of the cellular interactions required for enhancement of antibody production by the graft-versus-host reaction. J Exp Med (1972) 4.70
Dominance and crypticity of T cell antigenic determinants. Annu Rev Immunol (1993) 4.23
Determinant spreading and the dynamics of the autoimmune T-cell repertoire. Immunol Today (1993) 3.62
Thymus-independent antigens: the preparation of covalent, hapten-ficoll conjugates. J Immunol (1975) 3.62
The allogeneic effect in inbred mice. I. Experimental conditions for the enhancement of hapten-specific secondary antibody responses by the graft-versus-host reaction. J Exp Med (1972) 1.99
T cell regulation of immunoglobulin class expression in the antibody response to trinitrophenyl-ficoll. Evidence for T cell enhancement of the immunoglobulin class switch. J Exp Med (1982) 1.88
T-cell interactions in autoimmunity: insights from a murine model of graft-versus-host disease. Immunol Today (1989) 1.66
Effects of pH and polysaccharides on peptide binding to class II major histocompatibility complex molecules. Proc Natl Acad Sci U S A (1991) 1.49
Induction of IgE synthesis and potentiation of anti-ovalbumin IgE antibody response by HgCl2 in the rat. J Immunol (1981) 1.42
Mercuric chloride induces autoantibodies against U3 small nuclear ribonucleoprotein in susceptible mice. Proc Natl Acad Sci U S A (1989) 1.22
B-lymphocyte responses to trinitrophenyl-conjugated Ficoll: requirement for T lymphocytes and Ia-bearing adherent cells. Proc Natl Acad Sci U S A (1981) 1.12
Studies on the mechanism of drug sensitization: T-cell-dependent popliteal lymph node reaction to diphenylhydantoin. Clin Immunol Immunopathol (1981) 1.02
The popliteal lymph node assay in mice to screen for the immune disregulating potential of chemicals--a preliminary study. Int J Immunopharmacol (1989) 1.01
Murine systemic autoimmune disease induced by mercuric chloride: T helper cells reacting to self proteins. Int Arch Allergy Immunol (1996) 0.90
Immunopathological signs in mice treated with mercury compounds--I. Identification by the popliteal lymph node assay of responder and nonresponder strains. Int J Immunopharmacol (1988) 0.88
In vitro and in vivo allogeneic effects: differential modulation of B cell subpopulations. J Immunol (1982) 0.84
Predictive immunotoxicological test systems: suitability of the popliteal lymph node assay in mice and rats. Crit Rev Toxicol (1995) 0.84
Enhancement of antibody production by mercury and platinum group metal halide salts. Kinetics of total and ovalbumin-specific IgE synthesis. Int Arch Allergy Appl Immunol (1986) 0.82
Murine systemic autoimmune disease induced by mercuric chloride (HgCl2): Hg-specific helper T-cells react to antigen stored in macrophages. Int J Immunopharmacol (1993) 0.81
Comparison of the interaction of methyl mercury and mercuric chloride with murine macrophages. Arch Toxicol (1993) 0.80
Quantification of natural antibody producing B cells in rats by an improved ELISPOT technique using the polyvinylidene difluoride membrane as the solid support. J Immunol Methods (1995) 0.78
Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia (2009) 2.30
In vitro cellular drug resistance in children with relapsed/refractory acute lymphoblastic leukemia. Blood (1995) 2.00
Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands. Leukemia (2004) 1.71
Biological and therapeutic aspects of infant leukemia. Blood (2000) 1.70
Prednisolone resistance in childhood acute lymphoblastic leukemia: vitro-vivo correlations and cross-resistance to other drugs. Blood (1998) 1.69
Identification of new microRNA genes and aberrant microRNA profiles in childhood acute lymphoblastic leukemia. Leukemia (2008) 1.67
Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia. J Clin Oncol (2003) 1.67
mRNA expression levels of (co)chaperone molecules of the glucocorticoid receptor are not involved in glucocorticoid resistance in pediatric ALL. Leukemia (2005) 1.63
Relation between genetic variants of the ataxia telangiectasia-mutated (ATM) gene, drug resistance, clinical outcome and predisposition to childhood T-lineage acute lymphoblastic leukaemia. Leukemia (2005) 1.53
The MLL recombinome of acute leukemias. Leukemia (2006) 1.51
2-Chloro-s-triazine herbicides induce aromatase (CYP19) activity in H295R human adrenocortical carcinoma cells: a novel mechanism for estrogenicity? Toxicol Sci (2000) 1.48
Molecular determinants of glucocorticoid sensitivity and resistance in acute lymphoblastic leukemia. Leukemia (2003) 1.46
Long-term results of Dutch Childhood Oncology Group studies for children with acute lymphoblastic leukemia from 1984 to 2004. Leukemia (2009) 1.45
Do P-glycoprotein and major vault protein (MVP/LRP) expression correlate with in vitro daunorubicin resistance in acute myeloid leukemia? Leukemia (1999) 1.44
Ultrafine but not fine particulate matter causes airway inflammation and allergic airway sensitization to co-administered antigen in mice. Clin Exp Allergy (2006) 1.43
Organotin-induced apoptosis as observed in vitro is not relevant for induction of thymus atrophy at antiproliferative doses. Toxicol Appl Pharmacol (1997) 1.42
Assessment of the short-term functional outcome after urethroplasty: a prospective analysis. Int Braz J Urol (2012) 1.41
The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia. Br J Cancer (2005) 1.41
Prognostic significance of molecular-cytogenetic abnormalities in pediatric T-ALL is not explained by immunophenotypic differences. Leukemia (2007) 1.36
In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia. Blood (1997) 1.28
MicroRNAs in acute leukemia: from biological players to clinical contributors. Leukemia (2011) 1.26
Immunobiological diversity in infant acute lymphoblastic leukemia is related to the occurrence and type of MLL gene rearrangement. Leukemia (2007) 1.25
Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol. Leukemia (2009) 1.24
Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML). Leukemia (2002) 1.22
The heterogeneity of pediatric MLL-rearranged acute myeloid leukemia. Leukemia (2011) 1.21
Role of folylpolyglutamate synthetase and folylpolyglutamate hydrolase in methotrexate accumulation and polyglutamylation in childhood leukemia. Blood (1999) 1.20
Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML. Leukemia (2008) 1.18
Methods of in vitro toxicology. Food Chem Toxicol (2002) 1.18
NUP98/JARID1A is a novel recurrent abnormality in pediatric acute megakaryoblastic leukemia with a distinct HOX gene expression pattern. Leukemia (2013) 1.16
Comparison of the antileukemic activity in vitro of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. Med Pediatr Oncol (1996) 1.15
Discovery of new microRNAs by small RNAome deep sequencing in childhood acute lymphoblastic leukemia. Leukemia (2011) 1.15
Adjuvanticity of lactobacilli. I. Differential effects of viable and killed bacteria. Clin Exp Immunol (1979) 1.15
Toxicity of triorganotin compounds: comparative in vivo studies with a series of trialkyltin compounds and triphenyltin chloride in male rats. Toxicol Appl Pharmacol (1985) 1.13
Pharmacokinetic, pharmacodynamic and intracellular effects of PEG-asparaginase in newly diagnosed childhood acute lymphoblastic leukemia: results from a single agent window study. Leukemia (2008) 1.12
Clear cell sarcomas of the kidney registered on International Society of Pediatric Oncology (SIOP) 93-01 and SIOP 2001 protocols: a report of the SIOP Renal Tumour Study Group. Eur J Cancer (2013) 1.12
TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia. Blood (2000) 1.10
Components of the metabolic syndrome in 500 adult long-term survivors of childhood cancer. Ann Oncol (2009) 1.08
Src kinase-induced phosphorylation of annexin A2 mediates glucocorticoid resistance in MLL-rearranged infant acute lymphoblastic leukemia. Leukemia (2012) 1.08
EVI1 overexpression in distinct subtypes of pediatric acute myeloid leukemia. Leukemia (2010) 1.07
Outcome in children with Down's syndrome and acute lymphoblastic leukemia: role of IKZF1 deletions and CRLF2 aberrations. Leukemia (2012) 1.06
Posterior reversible encephalopathy syndrome in childhood cancer. Ann Oncol (2010) 1.06
A randomized trial investigating an exercise program to prevent reduction of bone mineral density and impairment of motor performance during treatment for childhood acute lymphoblastic leukemia. Pediatr Blood Cancer (2009) 1.05
mRNA expression levels of methotrexate resistance-related proteins in childhood leukemia as determined by a standardized competitive template-based RT-PCR method. Leukemia (2000) 1.05
The hunting of targets: challenge in miRNA research. Leukemia (2012) 1.05
The volume effect in paediatric oncology: a systematic review. Ann Oncol (2013) 1.04
Connectivity mapping identifies HDAC inhibitors for the treatment of t(4;11)-positive infant acute lymphoblastic leukemia. Leukemia (2011) 1.04
The pharmacokinetics of glycyrrhizic acid evaluated by physiologically based pharmacokinetic modeling. Drug Metab Rev (2001) 1.04
Biological activity of organotin compounds--an overview. Environ Res (1987) 1.03
Glucocorticoid receptor alpha, beta and gamma expression vs in vitro glucocorticod resistance in childhood leukemia. Leukemia (2004) 1.01
Glucocorticoid resistance in childhood leukemia. Leuk Lymphoma (1994) 1.01
Hypermethylation of specific microRNA genes in MLL-rearranged infant acute lymphoblastic leukemia: major matters at a micro scale. Leukemia (2010) 1.01
The popliteal lymph node assay in mice to screen for the immune disregulating potential of chemicals--a preliminary study. Int J Immunopharmacol (1989) 1.01
Low frequency of DNMT3A mutations in pediatric AML, and the identification of the OCI-AML3 cell line as an in vitro model. Leukemia (2011) 1.01
'Educational symposium on long-term results of large prospective clinical trials for childhood acute lymphoblastic leukemia (1985-2000)'. Leukemia (2010) 1.00
Aurora kinases in childhood acute leukemia: the promise of aurora B as therapeutic target. Leukemia (2012) 1.00
Mononuclear cells contaminating acute lymphoblastic leukaemic samples tested for cellular drug resistance using the methyl-thiazol-tetrazolium assay. Br J Cancer (1994) 0.99
Diesel exhaust, carbon black, and silica particles display distinct Th1/Th2 modulating activity. Toxicol Appl Pharmacol (2000) 0.98
L-asparaginase-induced severe necrotizing pancreatitis successfully treated with percutaneous drainage. Pediatr Blood Cancer (2005) 0.98
The effect of the food matrix on in vivo immune responses to purified peanut allergens. Toxicol Sci (2005) 0.98
In vitro drug-resistance profile in infant acute lymphoblastic leukemia in relation to age, MLL rearrangements and immunophenotype. Leukemia (2004) 0.97
Synergistic effect of 2,2',4,4',5,5'-hexachlorobiphenyl and 2,3,7,8-tetrachlorodibenzo-p-dioxin on hepatic porphyrin levels in the rat. Environ Health Perspect (1996) 0.97
Gain of 1q is a marker of poor prognosis in Wilms' tumors. Genes Chromosomes Cancer (2013) 0.97
CD4+CD25+ T cells regulate the intensity of hypersensitivity responses to peanut, but are not decisive in the induction of oral sensitization. Clin Exp Allergy (2007) 0.96
A new recurrent 9q34 duplication in pediatric T-cell acute lymphoblastic leukemia. Leukemia (2006) 0.95
The seventh international childhood acute lymphoblastic leukemia workshop report: Palermo, Italy, January 29--30, 2005. Leukemia (2005) 0.95
The prognostic significance of membrane transport-associated multidrug resistance (MDR) proteins in leukemia. Int J Clin Pharmacol Ther (2000) 0.95
Natural Hybrids of Phytophthora nicotianae and Phytophthora cactorum Demonstrated by Isozyme Analysis and Random Amplified Polymorphic DNA. Phytopathology (1998) 0.95
Organotins induce apoptosis by disturbance of [Ca(2+)](i) and mitochondrial activity, causing oxidative stress and activation of caspases in rat thymocytes. Toxicol Appl Pharmacol (2000) 0.95
Polymorphisms in folate-related genes: association with side effects of high-dose methotrexate in childhood acute lymphoblastic leukemia. Leukemia (2008) 0.95
High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation. Leukemia (2013) 0.94
Synergistic action of human recombinant tumor necrosis factor with endotoxins or nontoxic poly A:U against solid Meth A tumors in mice. Cancer Immunol Immunother (1987) 0.94
Incidence of additional genetic changes in the TEL and AML1 genes in DCOG and COALL-treated t(12;21)-positive pediatric ALL, and their relation with drug sensitivity and clinical outcome. Leukemia (2006) 0.94
Decreased serum anti-Müllerian hormone levels in girls with newly diagnosed cancer. Hum Reprod (2013) 0.94
In vitro drug sensitivity of normal peripheral blood lymphocytes and childhood leukaemic cells from bone marrow and peripheral blood. Br J Cancer (1991) 0.93
TBTC induces adipocyte differentiation in human bone marrow long term culture. Toxicology (2008) 0.93
Expression of a human homing receptor (CD44) in lymphoid malignancies and related stages of lymphoid development. Leukemia (1990) 0.93
MDR1 gene-related clonal selection and P-glycoprotein function and expression in relapsed or refractory acute myeloid leukemia. Blood (2001) 0.93
Cellular drug resistance profiles in childhood acute myeloid leukemia: differences between FAB types and comparison with acute lymphoblastic leukemia. Blood (2000) 0.92
TEL/AML1 fusion is not a prognostic factor in Dutch childhood acute lymphoblastic leukaemia. Br J Haematol (2001) 0.92
MiR-125b, miR-100 and miR-99a co-regulate vincristine resistance in childhood acute lymphoblastic leukemia. Leuk Res (2013) 0.92
Cellular and humoral adjuvant activity of mistletoe extract. Immunobiology (1979) 0.92
Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-beta-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeloid leukemia. Clin Cancer Res (1995) 0.91
Cooperative genetic defects in TLX3 rearranged pediatric T-ALL. Leukemia (2008) 0.91
Mixed antibody and T cell responses to peanut and the peanut allergens Ara h 1, Ara h 2, Ara h 3 and Ara h 6 in an oral sensitization model. Clin Exp Allergy (2004) 0.91
Effects of some persistent halogenated environmental contaminants on aromatase (CYP19) activity in the human choriocarcinoma cell line JEG-3. Toxicol Appl Pharmacol (1998) 0.91
Murine systemic autoimmune disease induced by mercuric chloride: T helper cells reacting to self proteins. Int Arch Allergy Immunol (1996) 0.90
Regulatory T-lymphocytes in asthma. Eur Respir J (2005) 0.90
Elevated S100A8/S100A9 expression causes glucocorticoid resistance in MLL-rearranged infant acute lymphoblastic leukemia. Leukemia (2012) 0.90
Germline variation in the MTHFR and MTRR genes determines the nadir of bone density in pediatric acute lymphoblastic leukemia: a prospective study. Bone (2010) 0.89
Toxicity of organotin compounds. I. Atrophy of thymus and thymus-dependent lymphoid tissue in rats fed di-n-octyltindichloride. Toxicol Appl Pharmacol (1976) 0.89
Dibutyltin and tributyltin compounds induce thymus atrophy in rats due to a selective action on thymic lymphoblasts. Int J Immunopharmacol (1988) 0.89
Improved flow cytometric detection of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia (2012) 0.89
Monoallelic or biallelic LMO2 expression in relation to the LMO2 rearrangement status in pediatric T-cell acute lymphoblastic leukemia. Leukemia (2007) 0.89
MDR 1 expression is an independent prognostic factor for response and survival in de novo acute myeloid leukaemia. Br J Haematol (1997) 0.88